Latest Headlines

Latest Headlines

MorphoSys posts solid early MOR202 data but still sees Genmab disappear into the distance

MorphoSys has released an early look at data from a Phase I/IIa trial of multiple myeloma drug MOR202. While the results are free from major red flags, the publication of Phase II data on Genmab and Johnson & Johnson's rival anti-CD38 drug just days earlier showed the scale of the task now facing MorphoSys.

MorphoSys swoops for Lanthio as biotech investment plan matures

MorphoSys has acquired Lanthio Pharma. The deal comes 30 months after MorphoSys originally hooked up with Lanthio, which was the first company to receive an investment from its biotech financing initiative.

MorphoSys bags a peptide biotech for $22M

MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($22 million) for the shares it didn't already own and picking up a handful of peptide candidates.

MorphoSys: That Celgene-abandoned cancer drug isn't dead yet

Germany's MorphoSys is moving on after the surprise cancelation of a Celgene partnership spooked investors and battered the company's share price, with CEO Simon Moroney preaching patience for an early-stage cancer candidate.

MorphoSys tanks after Celgene walks away from $818M pact

Celgene has walked away from its $818 million multiple myeloma co-development pact with MorphoSys less than two years after striking the deal. The decision means Celgene has nothing to show for the $92 million upfront payment it made in 2013, but MorphoSys was hit harder by the news.

MorphoSys bets on Emergent BioSolutions' cancer contender in $183M deal

German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.

Merck KGaA tackles hot immuno-oncology field in partnership with MorphoSys

MorphoSys has notched another high-profile pharma partnership on its belt of antibody deals, and it's set its sights on immune checkpoint inhibitors. With this pact, Merck KGaA is also staking out a position on the growing roster of companies scrambling to find a profitable place for itself in immuno-oncology.

Novartis' 'breakthrough' muscle drug is worth $4B, if you ask MorphoSys

Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.

MorphoSys grabs $126M for clinical trial work

The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 antibody currently in a Phase I/IIa clinical trial in multiple myeloma.

Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal

Celgene has decisively stepped in to partner on an early-stage myeloma and leukemia drug in MorphoSys's pipeline, paying $92 million upfront, a $60 million premium for a stake in the company and offering to cover a substantial portion of the R&D budget for the antibody targeting the CD38 molecule.